Rilemo develops diagnostic and monitoring solutions to support clinicians throughout the patient pathway. The company focuses on providing tools for the detection and monitoring of fluid-related pathologies. This technology aims to assist healthcare professionals in diagnosis and ongoing patient management, regardless of location.
Funding
Funding not disclosed
Founders
Product
Problem
Current diagnostic methods for conditions like edema, cancer, and hemorrhagic events often rely on symptom presentation, leading to late diagnoses and potentially increasing patient mortality, especially in emergency settings. Traditional imaging technologies can be expensive, bulky, and not readily accessible in all clinical environments.
Solution
Rilemo is developing a portable, AI-powered imaging device designed to detect medical conditions related to fluid imbalances, such as edema and hemorrhage, at early stages. The device aims to provide rapid assessment capabilities in diverse settings, enabling timely diagnosis and monitoring of patients. By leveraging artificial intelligence, the system analyzes images to identify subtle indicators of disease, potentially improving diagnostic accuracy and reducing delays in treatment. The company envisions a future where late diagnoses are minimized through accessible and proactive diagnostic tools.
Target Audience
The primary target audience includes healthcare professionals, such as doctors and hospitals, who require tools for early diagnosis, monitoring, and follow-up of patients with fluid-related pathologies.
Features
- Portable imaging device for on-the-go medical assessments
- AI-powered analysis for early detection of fluid-related pathologies
- Intended for use in various healthcare settings, including emergency care